UBS Group
MGRM

UBS Group’s Monogram Orthopaedics MGRM Stock Holding History

UBS Group’s Portfolio MGRM Stock Details MGRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,536
Closed -$14.9K – 10923
2025
Q3 		$14.9K Sell
2,536
-22,592
-90% -$121K ﹤0.01% 8341
2025
Q2 		$72.6K Buy
+25,128
New +$67.7K ﹤0.01% 7486
2025
Q1 		– Sell
-4,521
Closed -$10.7K – 10533
2024
Q4 		$10.7K Sell
4,521
-916
-17% -$2.15K ﹤0.01% 8282
2024
Q3 		$14.4K Sell
5,437
-14,750
-73% -$38.4K ﹤0.01% 7546
2024
Q2 		$43.4K Buy
20,187
+13,680
+210% +$30K ﹤0.01% 6805
2024
Q1 		$15.9K Buy
6,507
+6,207
+2,069% +$18.3K ﹤0.01% 7025
2023
Q4 		$1.03K Sell
300
-40,510
-99% -$122K ﹤0.01% 8426
2023
Q3 		$106K Sell
40,810
-3,846
-9% -$16.2K ﹤0.01% 5797
2023
Q2 		$178K Buy
+44,656
New +$231K ﹤0.01% 5568

UBS Group's MGRM Position: Q4 2025 in Review

UBS Group sold out of Monogram Orthopaedics (MGRM) in Q4 2025, closing a stake of 2,536 shares — an estimated $14.9K sold.

UBS Group first reported a position in MGRM in Q2 2023 and held it in 9 quarters. The position peaked at $178K in Q2 2023. 0 funds tracked by Wall St. Rank hold MGRM as of Q4 2025.

  • UBS Group reported no remaining Monogram Orthopaedics position as of Q4 2025 after selling out during the quarter.
  • UBS Group sold 2,536 Monogram Orthopaedics shares in Q4 2025, an estimated $14.9K.
  • UBS Group first reported a position in Monogram Orthopaedics in Q2 2023 and held it in 9 quarters.
  • UBS Group's Monogram Orthopaedics position peaked at $178K in Q2 2023.
  • 0 funds tracked by Wall St. Rank held Monogram Orthopaedics as of Q4 2025.

Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.